Logo image of SRT3.DE

SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:SRT3 - DE0007165631

249.55 EUR
-3.9 (-1.54%)
Last: 1/20/2026, 9:53:04 AM
Fundamental Rating

3

SRT3 gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 20 industry peers in the Life Sciences Tools & Services industry. SRT3 has a bad profitability rating. Also its financial health evaluation is rather negative. SRT3 is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • SRT3 had positive earnings in the past year.
  • In the past year SRT3 had a positive cash flow from operations.
  • In the past 5 years SRT3 has always been profitable.
  • SRT3 had a positive operating cash flow in each of the past 5 years.
SRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFSRT3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • SRT3 has a worse Return On Assets (1.39%) than 85.00% of its industry peers.
  • With a Return On Equity value of 5.01%, SRT3 is not doing good in the industry: 75.00% of the companies in the same industry are doing better.
  • SRT3's Return On Invested Capital of 4.71% is on the low side compared to the rest of the industry. SRT3 is outperformed by 80.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for SRT3 is in line with the industry average of 9.00%.
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROIC 4.71%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
SRT3.DE Yearly ROA, ROE, ROICSRT3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 3.80%, SRT3 is doing worse than 85.00% of the companies in the same industry.
  • SRT3's Profit Margin has declined in the last couple of years.
  • SRT3 has a Operating Margin of 14.06%. This is in the lower half of the industry: SRT3 underperforms 75.00% of its industry peers.
  • SRT3's Operating Margin has declined in the last couple of years.
  • The Gross Margin of SRT3 (46.48%) is better than 70.00% of its industry peers.
  • SRT3's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
SRT3.DE Yearly Profit, Operating, Gross MarginsSRT3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SRT3 is destroying value.
  • Compared to 1 year ago, SRT3 has more shares outstanding
  • The number of shares outstanding for SRT3 has been increased compared to 5 years ago.
  • The debt/assets ratio for SRT3 has been reduced compared to a year ago.
SRT3.DE Yearly Shares OutstandingSRT3.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SRT3.DE Yearly Total Debt VS Total AssetsSRT3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • SRT3 has an Altman-Z score of 2.51. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.51, SRT3 is doing worse than 60.00% of the companies in the same industry.
  • SRT3 has a debt to FCF ratio of 8.92. This is a slightly negative value and a sign of low solvency as SRT3 would need 8.92 years to pay back of all of its debts.
  • The Debt to FCF ratio of SRT3 (8.92) is worse than 75.00% of its industry peers.
  • A Debt/Equity ratio of 1.28 is on the high side and indicates that SRT3 has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.28, SRT3 is doing worse than 85.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Altman-Z 2.51
ROIC/WACC0.56
WACC8.43%
SRT3.DE Yearly LT Debt VS Equity VS FCFSRT3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 0.95 indicates that SRT3 may have some problems paying its short term obligations.
  • The Current ratio of SRT3 (0.95) is worse than 90.00% of its industry peers.
  • SRT3 has a Quick Ratio of 0.95. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.49, SRT3 is doing worse than 95.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.49
SRT3.DE Yearly Current Assets VS Current LiabilitesSRT3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 59.34% over the past year.
  • The earnings per share for SRT3 have been decreasing by -11.87% on average. This is quite bad
  • The Revenue has been growing slightly by 5.82% in the past year.
  • SRT3 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.10% yearly.
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%

3.2 Future

  • SRT3 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.87% yearly.
  • Based on estimates for the next years, SRT3 will show a quite strong growth in Revenue. The Revenue will grow by 8.45% on average per year.
EPS Next Y22.67%
EPS Next 2Y21.45%
EPS Next 3Y22.86%
EPS Next 5Y18.87%
Revenue Next Year5.32%
Revenue Next 2Y6.73%
Revenue Next 3Y8.71%
Revenue Next 5Y8.45%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SRT3.DE Yearly Revenue VS EstimatesSRT3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
SRT3.DE Yearly EPS VS EstimatesSRT3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 54.73, which means the current valuation is very expensive for SRT3.
  • SRT3's Price/Earnings ratio is rather expensive when compared to the industry. SRT3 is more expensive than 90.00% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.38, SRT3 is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 41.29, the valuation of SRT3 can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a rather expensive valuation: SRT3 more expensive than 90.00% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 24.29. SRT3 is valued rather expensively when compared to this.
Industry RankSector Rank
PE 54.73
Fwd PE 41.29
SRT3.DE Price Earnings VS Forward Price EarningsSRT3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SRT3 indicates a slightly more expensive valuation: SRT3 is more expensive than 60.00% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, SRT3 is valued a bit more expensive than the industry average as 60.00% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 39.04
EV/EBITDA 24.68
SRT3.DE Per share dataSRT3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates SRT3 does not grow enough to justify the current Price/Earnings ratio.
  • A more expensive valuation may be justified as SRT3's earnings are expected to grow with 22.86% in the coming years.
PEG (NY)2.41
PEG (5Y)N/A
EPS Next 2Y21.45%
EPS Next 3Y22.86%

4

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.37%, SRT3 is not a good candidate for dividend investing.
  • SRT3's Dividend Yield is comparable with the industry average which is at 0.54.
  • Compared to an average S&P500 Dividend Yield of 1.84, SRT3's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.37%

5.2 History

  • The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • SRT3 pays out 37.92% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of SRT3 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP37.92%
EPS Next 2Y21.45%
EPS Next 3Y22.86%
SRT3.DE Yearly Income VS Free CF VS DividendSRT3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
SRT3.DE Dividend Payout.SRT3.DE Dividend Payout, showing the Payout Ratio.SRT3.DE Dividend Payout.PayoutRetained Earnings

SARTORIUS AG-VORZUG

FRA:SRT3 (1/20/2026, 9:53:04 AM)

249.55

-3.9 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-16
Earnings (Next)02-03
Inst Owners4.42%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.69B
Revenue(TTM)3.52B
Net Income(TTM)133.70M
Analysts80
Price Target387.02 (55.09%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.37%
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP37.92%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.85%
Min EPS beat(2)-10.52%
Max EPS beat(2)4.83%
EPS beat(4)1
Avg EPS beat(4)-3.47%
Min EPS beat(4)-10.52%
Max EPS beat(4)4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.83%
Revenue beat(4)3
Avg Revenue beat(4)1.91%
Min Revenue beat(4)-0.73%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.49%
PT rev (3m)22.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.45%
EPS NY rev (1m)-0.02%
EPS NY rev (3m)-0.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.17%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)0.17%
Valuation
Industry RankSector Rank
PE 54.73
Fwd PE 41.29
P/S 5.31
P/FCF 39.04
P/OCF 21.37
P/B 7
P/tB N/A
EV/EBITDA 24.68
EPS(TTM)4.56
EY1.83%
EPS(NY)6.04
Fwd EY2.42%
FCF(TTM)6.39
FCFY2.56%
OCF(TTM)11.68
OCFY4.68%
SpS46.97
BVpS35.63
TBVpS-35.24
PEG (NY)2.41
PEG (5Y)N/A
Graham Number60.46
Profitability
Industry RankSector Rank
ROA 1.39%
ROE 5.01%
ROCE 6.33%
ROIC 4.71%
ROICexc 4.98%
ROICexgc 17.77%
OM 14.06%
PM (TTM) 3.8%
GM 46.48%
FCFM 13.61%
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexgc growth 3Y-35.26%
ROICexgc growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 1.28
Debt/FCF 8.92
Debt/EBITDA 3.69
Cap/Depr 92.32%
Cap/Sales 11.25%
Interest Coverage 2.65
Cash Conversion 94.72%
Profit Quality 357.97%
Current Ratio 0.95
Quick Ratio 0.49
Altman-Z 2.51
F-Score7
WACC8.43%
ROIC/WACC0.56
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)59.34%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%24.14%
EPS Next Y22.67%
EPS Next 2Y21.45%
EPS Next 3Y22.86%
EPS Next 5Y18.87%
Revenue 1Y (TTM)5.82%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%6.25%
Revenue Next Year5.32%
Revenue Next 2Y6.73%
Revenue Next 3Y8.71%
Revenue Next 5Y8.45%
EBIT growth 1Y18.65%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year101.42%
EBIT Next 3Y38.38%
EBIT Next 5Y26.17%
FCF growth 1Y123.33%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y6.61%
OCF growth 3Y4.07%
OCF growth 5Y20.79%

SARTORIUS AG-VORZUG / SRT3.DE FAQ

What is the ChartMill fundamental rating of SARTORIUS AG-VORZUG (SRT3.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRT3.DE.


Can you provide the valuation status for SARTORIUS AG-VORZUG?

ChartMill assigns a valuation rating of 1 / 10 to SARTORIUS AG-VORZUG (SRT3.DE). This can be considered as Overvalued.


Can you provide the profitability details for SARTORIUS AG-VORZUG?

SARTORIUS AG-VORZUG (SRT3.DE) has a profitability rating of 3 / 10.


What is the valuation of SARTORIUS AG-VORZUG based on its PE and PB ratios?

The Price/Earnings (PE) ratio for SARTORIUS AG-VORZUG (SRT3.DE) is 54.73 and the Price/Book (PB) ratio is 7.


Can you provide the financial health for SRT3 stock?

The financial health rating of SARTORIUS AG-VORZUG (SRT3.DE) is 1 / 10.